Nurix Therapeutics (NRIX) said Thursday the US Food and Drug Administration has granted Fast Track designation for NX-5948 to treat adults with relapsed or refractory Waldenstrom's macroglobulinemia after at least two lines of therapy.
Fast Track designation is intended to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the company said.
Waldenstrom's macroglobulinemia is a rare, slow growing type of non-Hodgkin's lymphoma in which normal bone marrow cells are replaced by malignant lymphocytic cells, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。